Need professional-grade analysis? Visit stockanalysis.com
$43.85M
N/A
N/A
N/A
Microba Life Sciences Ltd (MAP) trades on Australian Securities Exchange in AUD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at AUD0.07, down 4.05% from the previous close.
Over the past year, MAP has traded between a low of AUD0.07 and a high of AUD0.23. The stock has lost 60.6% over this period. It is currently 68.4% below its 52-week high.
Microba Life Sciences Ltd has a market capitalization of $43.85M.
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Side-by-side comparison against top Healthcare peers.